Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer ...

A group of advanced practice providers discuss treatment options for a woman with newly diagnosed, transplant-ineligible ...

During an episode of of The Vitals, Jessica Fox, RN, a radiation oncology nurse with the Providence Cancer Institute in ...

Panelists discuss how the care team identifies and manages symptoms in chronic graft-versus-host disease patients, particularly those with advanced disease, emphasizing key symptoms to monitor, ...

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

A nurse practitioner discusses her role in caring for patients with multiple myeloma, and how advanced practice providers ...

Experts discuss prophylactic measures for managing potential adverse events associated with talquetamab and other bispecifics ...

During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...

The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

Nivolumab, given with or without ipilimumab, showed durable 10-year survival outcomes in patients with advanced melanoma.